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Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs). The
aim of this study was to determine the incidence of and risk factors for SAEs due to PZA dur-
ing first-line anti-tuberculosis treatment.
Methods
The medical records of patients with tuberculosis (TB) treated with PZA-containing regi-
mens including first-line drugs—ethambutol, rifampicin, and isoniazid—from January 2003
to June 2016 were reviewed. SAEs were defined as side effects that led to drug discontinua-
tion. The causative drug was determined based on the disappearance of the SAEs upon
drug withdrawal and/or the recurrence of the same SAEs with re-challenge.
Results
Of 2,478 patients with TB, 16.4% experienced SAEs. The incidence of SAEs increased sig-
nificantly as age increased, except with rifampin. PZA accounted for most SAEs (55.8%).
Hepatotoxicity was the most common SAE due to PZA (44.5%), followed by gastrointestinal
(GI) intolerance (23.8%). The risk of SAEs due to PZA increased significantly as age
increased, when sex and comorbidities were adjusted (odds ratio, 1.013; 95% confidence
interval, 1.004–1.023; P = 0.007). In the subgroup analysis, older age was an independent
risk factor for GI intolerance but not for hepatotoxicity.
Conclusion
PZA was the most common drug associated with SAEs among the first-line anti-TB drugs,
and old age was an independent factor for SAE occurrence. This study suggests that the
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early recognition of whether the causative agent is PZA may improve effective treatment
compliance, particularly in elderly patients.
Introduction
Tuberculosis (TB) is a major cause of death worldwide [1]. Although a standard oral regimen can
successfully treat up to 80% of drug-susceptible strains [2], TB is a significant threat to public
health systems because of the difficulties in early detection and the required treatment duration
[3, 4]. The current guidelines for TB treatment recommend that standard oral drugs—isoniazid
(INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA)—be administered at least
for 6 months, with an initial intensive phase followed by a continuation phase [5]. During the
treatment period, approximately 8–85% of patients experience various side effects, which range
from mild to severe [6]. Severe and fatal drug reactions, or serious adverse events (SAEs) [7, 8],
occur in approximately 10–25% of patients who experience side effects [9, 10]. Patients who take
medication irregularly or discontinue treatment owing to adverse effects require a longer duration
of therapy and are at risk of treatment failure, relapse, or the development of resistance [8, 11–14].
As societal aging progresses, the development of TB in the elderly is increasing [15]. Con-
sidering that older age is a notable risk factor for SAEs [9, 16, 17] owing to several comorbidi-
ties [18] or polypharmacy [19], healthcare providers who manage TB must exercise caution
while selecting suitable anti-TB drugs and doses and monitor compliance. According to previ-
ous studies, pyrazinamide causes the most SAEs among first-line anti-TB drugs [9, 10, 20].
However, there is limited information regarding the safety of PZA in elderly patients [21, 22].
In particular, the incidence and types of SAEs and their relationship with patient age have not
been thoroughly investigated previously. Therefore, we aimed to demonstrate the relationship
of age and type of SAE to PZA.
Material and methods
Study design and patients
We conducted a retrospective cohort study at Seoul National University Bundang Hospital on
patients diagnosed with active pulmonary or extra-pulmonary TB who were treated with standard
first-line anti-TB medication (INH, RIF, EMB, and PZA) from May 2003 to June 2016. To investi-
gate the time of SAE onset, we excluded patients with treatment failure or death and whose clinical
data were insufficient. Additional exclusion criteria were as follows: (i) multi-drug-resistant TB; (ii)
non-tuberculosis mycobacterium lung disease; (iii) aged<18 years; (iv) insufficient clinical data
owing to transfer, permanent discontinuation of all medications irrespective of cause, loss to follow
up, or death; or (v) positive human immunodeficiency virus serology. The analysis of patients who
died or discontinued anti-TB therapy is provided in Online Supplementary S1 Table).
This study was conducted in accordance with the amended Declaration of Helsinki [23].
The Institutional Review Board of Seoul National University Bundang Hospital approved the
study protocol and waived the need for informed consent owing to the retrospective study
design (IRB No. B- 1608-357-113).
Definition of terms
An SAE was defined as any drug reaction that led to the discontinuation of medication owing
to side effects that were intractable to conventional treatment. These events were classifiable as
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hepatotoxicity, cutaneous reaction, gastrointestinal (GI) intolerance, or arthralgia [12]. Hepa-
totoxicity was defined as a transaminase level more than three times greater than normal with
associated symptoms such as nausea, vomiting, or abdominal pain or a transaminase level
more than five times greater than the upper limit without symptoms. Cutaneous reactions
included rash, itching sensation, and eruption, and GI intolerance included nausea, vomiting,
and abdominal pain unrelated to hepatotoxicity. Arthropathy included acute gout and articu-
lar pain and was clinically diagnosed. The causative drug was determined based on the disap-
pearance of the SAEs upon the withdrawal of the most suspected drug without re-challenge or
the recurrence of the same SAE with drug re-challenge. In cases of withdrawal, the decision
regarding the discontinuation of the suspected drug was made by the attending physicians [9].
According to the American Thoracic Society guidelines for TB treatment, the standard regi-
men is defined as a four-drug combination based on body weight as follows: 300 mg/day INH,
10 mg/kg/day RIF, 15–20 mg/kg/day EMB, and 25 mg/kg/day PZA [5]. At least 2 months of
the intensive phase and 4 months of the continuation phase should be applied based on cur-
rent practice guidelines [5].
Statistical analysis
Data were analyzed using SPSS software for Windows version 25.0 (SPSS Inc., Armonk, New
York, USA). The baseline characteristics of the study groups are expressed as the mean and
standard deviation (SD). Differences between the ‘no SAE’ and ‘SAE’ groups were analyzed
using independent t-tests for continuous variables and χ2 or Fisher’s exact tests for categorical
variables. Differences were considered significant when P< 0.05. In logistic regression, vari-
ables were selected based on a univariate analysis. The inclusion criterion for a variable was a
significance level of< 0.1.
Results
Baseline characteristics
In total, 3,384 patients prescribed anti-TB medication were screened, and 2,478 patients diag-
nosed with pulmonary or extra-pulmonary TB met the study criteria (Fig 1). The median age
of the patients was 49.6 years, with pulmonary TB predominating (84.8%), and 53.2% were
male. Among the patients, 407 (16.4%) experienced an SAE due to a first-line anti-TB drug
during the study period. The median duration of time between the recognition of the SAEs
and the first follow-up was 9.0 days (interquartile range, 7.0–14.0 days).
The drug most commonly associated with SAEs was PZA (N = 227, 9.2%), followed by
EMB (N = 95, 3.8%), RIF (N = 56, 2.3%), and INH (N = 26, 1.0%) (Fig 1). Among the 227
patients who experienced SAEs due to PZA, 188 (82.8%) and 39 (17.2%) cases were identified
by withdrawal and re-challenge, respectively. There were significant differences between
patients with SAEs and without SAEs due to PZA with regard to age (49.0 ± 18.3 years vs.
55.5 ± 18.5 years, P< 0.001) and treatment duration (7.9 ± 3.1 months vs. 9.2 ± 3.4 months,
P< 0.001, Table 1). Positive hepatitis B or C serology and baseline liver function tests were not
different between the two groups. In cases of death or treatment discontinuation, 44.4% (75/
169) of patients experienced a SAE, and the rate of SAEs due to PZA (37.3%) was considerably
higher than that due to other drugs (Online Supplementary S1 Table).
Types of serious adverse events
The incidence rate of hepatotoxicity was the highest (4.7%, 116/2478), followed by cutaneous
adverse reaction (3.6%, 89/2478) and GI intolerance (2.9%, 71/2478, Fig 2). According to
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specific drugs, hepatotoxicity due to PZA was the most common adverse effect, affecting
87.1% of patients (101/116). Cutaneous and GI adverse reactions due to PZA accounted for
40.4% (36/89) and 76.1% (54/71), respectively. Arthropathy, a PZA-specific SAE, occurred in
27 patients. The median onset time of SAEs due to PZA was 22.0 days from treatment initia-
tion, but arthropathy occurred later than the other SAEs (Table 2).
Risk factors for serious adverse events
Among the patients who experienced SAEs due to the first-line anti-TB drugs, the overall inci-
dence of SAEs was significantly greater with increasing age (P< 0.001, Fig 3). These age-inci-
dence relationships were observed with all drugs, except RIF. In the univariate analysis, age
and diabetes mellitus (DM) were significant predictive factors for the occurrence of SAEs due
to PZA. In the multivariate analysis, age was also identified as an independent risk factor for
SAEs due to PZA, when sex and underlying comorbidities, such as chronic liver disease and
DM, were adjusted (odds ratio, 1.013; 95% confidence interval [CI], 1.004–1.023; P = 0.007,
Table 3). Subgroup analysis according to the type of SAE is shown in Online Supplementary
S2–S5 Tables. There were significant differences between patients with and without GI intoler-
ance with regard to age, sex, and history of DM, whereas no associated factors were observed
in patients with hepatotoxicity, skin rash, and arthropathy.
Discussion
In this study, adverse effects that led to the interruption or discontinuation of medication
occurred in 16.4% of patients, and PZA was the most common causative drug. Although the
overall incidence of SAEs increased as age increased, age was not associated with the individual
SAEs, except for GI intolerance. Hepatotoxicity was not related to age, which has clinical
implications for the treatment of TB. First, although we analyzed only patients who had
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0236109.g001
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follow-up data from initiation to end of treatment, the incidence of SAEs was not uncommon
and would have likely been higher if patients with treatment failure or those who were lost to
follow-up had been included. This emphasizes the importance of recognizing SAEs early and
highlights the need to modify drug regimens to prevent drug-related morbidity and mortality
and improve treatment adherence. Second, because elderly patients are more likely to be vul-
nerable to anti-TB medication, physicians should be particularly aware of SAEs when treating
older patients with TB. Third, the high confirmation rate as a causative drug by only de-chal-
lenging might suggest that physicians preferentially discontinued PZA because it was not a
maintenance drug and as previously reported side effects were high. Thus, although PZA is an
elementary drug and contributes to reducing treatment duration, it is essential to consider its
risks and benefits for individual patients when choosing TB medication.
In previous studies, SAEs were most commonly attributable to PZA [9, 10, 20]. Among the
SAEs, hepatotoxicity was substantially more common than other types of adverse events. Old
age, female sex, treatment regimen, abnormal liver function test at baseline, and previous
Table 1. Baseline characteristics of the 2484 patients with tuberculosis according to the occurrence of severe adverse events due to pyrazinamide.
Variables Total Serious adverse events due to PZA P value
N = 2478 (–), N = 2251 (+), N = 227
Age (year) 49.6±18.4 49.0±18.3 55.5±18.5 <0.001
Sex, male (%) 1319 (53.2) 1048 (46.6) 111 (48.9) 0.500
Tuberculosis 0.291
Pulmonary 2102 (84.8) 1904 (84.6) 198 (87.2)
Extrapulmonary 376 (15.2) 347 (15.4) 29 (12.8)
Initial diagnosis 0.524
Sputum AFB 791 (33.7) 722 (33.9) 69 (31.8)
TB-PCR 1553 (66.3) 1405 (66.1) 148 (68.2)
Comorbidities
DM 244 (9.8) 214 (9.5) 30 (13.2) 0.074
Malignancy 133 (5.4) 117 (5.2) 16 (7.0) 0.238
Renal insufficiency 26 (1.0) 20 (1.0) 4 (1.8) 0.291
Smokinga 0.718
Never 1069 (56.8) 871 (56.6) 198 (57.7)
Ex- or current 814 (43.2) 669 (43.4) 145 (42.3)
Alcohol useb 0.553
Never/social 618 (89.7) 473 (89.2) 145 (91.2)
Heavy 71 (10.3) 57 (10.8) 14 (8.8)
Long-term steroid use 4 (0.2) 4 (0.2) 0 (0.0) 1.000
Risk factors for hepatotoxicity
HBs Ag (+) 57 (4.2) 51 (4.2) 6 (4.0) 0.912
Anti HCV (+) 12 (0.9) 12 (1.0) 0 (0.0) 0.381
Initial laboratory tests
AST 22.0±11.8 21.8±11.1 24.2±16.8 0.090
ALT 19.4±14.6 19.4±14.8 19.6±13.5 0.881
Treatment duration (mo.) 8.0±3.1 7.9±3.1 9.2±3.4 <0.001
AFB, acid-fast blue; TB, tuberculosis; PCR, polymerase chain reaction; DM, diabetes mellitus;
aData were not recorded for 595 (24.0%) patients.
bData were not recorded for 1789 (72.2%) patients.
Data are reported as the mean ± standard deviation and numbers (%).
https://doi.org/10.1371/journal.pone.0236109.t001
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history of hepatitis were reported to be risk factors for PZA-associated hepatotoxicity [7, 24,
25]. Although the exact mechanism of hepatotoxicity is not fully understood, drug metabolism
rather than the peak drug level might contribute to the development of hepatotoxicity to PZA.
For instance, an animal study showed that two PZA metabolites, pyrazinoic acid and 5-hydro-
xypyrazinoic acid, are responsible for hepatotoxicity [26]. In contrast, several studies measur-
ing the serum PZA level revealed that the occurrence of hepatotoxicity was not significantly
related to the drug concentration [20, 27]. As drug-drug interaction owing to polypharmacy
[28] and physiological changes such as decreased hepatic blood flow in the elderly [29] might
affect the pharmacodynamics and pharmacokinetics of drugs, elderly patients may be more
likely to experience hepatotoxicity. In our study, a relationship between age and the develop-
ment of hepatotoxicity was not identified. Additionally, a recently published prospective study
with 89 patients aged 80 or older showed that a PZA-containing regimen does not increase the
rate of hepatotoxicity compared to INH-, RIF-, and EMB-containing regimens, which is con-
sistent with our results [22]. Considering that PZA is a cornerstone drug for the treatment of
TB, further studies on biomarkers to predict the occurrence of hepatotoxicity are warranted.
Fig 2. The proportion of each anti-tuberculosis drug related to severe adverse events.
https://doi.org/10.1371/journal.pone.0236109.g002
Table 2. Types and onset time of severe adverse events due to PZA.
Variables No. patients (%) Time of onset (days, IQR)
Total 227 (100.0) 22.0 (14.0–42.0)
Hepatotoxicity 101 (44.5) 27.0 (14.0–47.5)
GI intolerance 54 (23.8) 18.0 (11.8–33.8)
Cutaneous adverse reactions 36 (15.9) 19.5 (12.0–37.3)
Arthropathy 27 (11.9) 42.0 (21.0–59.0)
Others† 9 (4.0) 15.0 (12.5–18.5)
PZA, pyrazinamide; IQR, interquartile range; GI, gastrointestine.
Data are reported as the median (range) and numbers (%).
† Paraesthesia in 4 (1.4%), general weakness in 2 (0.7%), central nervous symptoms in 2 (0.7%) and
thrombocytopenia in 1 (0.4%).
https://doi.org/10.1371/journal.pone.0236109.t002
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GI intolerance was the second most frequent SAE due to PZA in our study. Unlike other
SAEs, older age was the greatest risk factor for GI intolerance, along with female sex and DM.
Kwon et al. reported that GI intolerance occurs at a high rate in the elderly (�65 years), affect-
ing 10% of the older group [30]. Yee et al. showed that age over 60 is an independent risk factor
for GI problems but that this is not the case in those under 35 (hazard ratio, 6.4; 95% CI, 1.2–
3.6), which support our results. In contrast, Xiaozhen et al. reported that severe GI disorders
occur in less than 1% of the total patients [31]. This study included younger patients, more
males, and a lower proportion of patients with DM than our study. These conflicting results
might be attributed to demographic factors and underlying medical conditions. As gastropar-
esis affects 40% of longstanding patients with DM [32], GI disorders due to PZA might be syn-
ergistic with DM gastropathy. Therefore, in cases of elderly patients with DM who suffer from
GI motility disorders, PZA should be administered with caution.
Cutaneous adverse reactions also represented a frequently observed SAE in our study.
Overall, the incidence of cutaneous adverse reactions due to anti-TB medication varies across
studies, and the results for the most common causative drugs also differ [9, 33, 34]. For
instance, Marra et al. reported that an EMB-containing regimen tends to increase the risk of
cutaneous adverse reactions, though there is no statistically significant difference [33]. Simi-
larly, in a study by Kim et al., 16.8% of patients experienced severe cutaneous adverse
Fig 3. Incidence of serious adverse events due to pyrazinamide according to age group.
https://doi.org/10.1371/journal.pone.0236109.g003
Table 3. Risk factors for the occurrence of severe adverse events due to pyrazinamide.
Variables Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Age (year) 1.019 1.012–1.027 <0.001 1.013 1.004–1.023 0.007
Sex, Male (%) 0.910 0.693–1.196 0.500 1.245 0.881–1.760 0.214
Chronic liver disease 0.868 0.367–2.051 0.747 0.944 0.398–2.240 0.896
DM 1.450 0.963–2.182 0.075 1.039 0.628–1.719 0.883
Renal insufficiency 1.817 0.621–5.321 0.276
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus.
https://doi.org/10.1371/journal.pone.0236109.t003
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reactions, and SAEs due to EMB were more common (6.2%) than those to PZA (3.7%) [34]. In
contrast, Yee et al. reported that the incidence of severe rash is mostly associated with PZA [9].
These inconsistent results might be attributed to differences in treatment duration or other
concomitant medications. Although the incidence of PZA-associated cutaneous reactions var-
ies and is more rarely reported than other types of SAEs, physicians should note that PZA also
causes cutaneous reactions.
Our study had several limitations. First, the study was conducted at a single center with a
retrospective design. Additionally, there were no set protocols for following or managing
SAEs. Nonetheless, a small group of physicians were involved in diagnosing and treating TB
via a consistent approach to manage side effects; thus, bias was reduced. In addition, analysis
based on a large number of subjects confers robust evidence. Second, because we only included
patients who had sufficient data to evaluate the SAEs of individual drugs, SAEs in patients who
died or discontinued treatment may have been underestimated in terms of frequency. Never-
theless, when death or early discontinuation cases were included, PZA was shown to be the
most common SAE-causing drug. Third, data regarding risk factors for hepatotoxicity, such as
viral hepatitis or history of alcohol consumption, were missing for a large number of patients.
Testing for viral hepatitis is not routinely carried out before anti-TB treatment, and only 55.2%
of patients had available data in this analysis. Fourth, although we defined SAEs as cases
requiring discontinuation or interruption of anti-TB medication, we did not further classify
each SAE by severity. Therefore, further investigation into the association between SAE sever-
ity and drug treatment is warranted.
Conclusions
The incidence of SAEs due to PZA was 9.2%, and old age was a notable risk factor for SAE
occurrence. In the majority of cases, a causal relationship was identified by the withdrawal of
PZA, even without re-challenge. Therefore, the importance of the early recognition of SAEs
and decisions regarding whether to discontinue should be emphasized to ensure effective
treatment compliance, especially in elderly patients.
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